Do analysts rate AVTE or MBX?

MBX Biosciences has a consensus target price of $60.22, indicating a potential upside of 2.04%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MBX Biosciences 2 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.77

Which has stronger earnings & valuation, AVTE or MBX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A MBX Biosciences N/A N/A -$86.97M -$2.21 N/A

Is AVTE or MBX more profitable?

MBX Biosciences' return on equity of -24.52% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% MBX Biosciences N/A -24.52% -23.59%

Do analysts recommend ABCL or AVTE?

AbCellera Biologics presently has a consensus target price of $8.33, indicating a potential upside of 5.66%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe AbCellera Biologics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbCellera Biologics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate NRIX or AVTE?

Nurix Therapeutics presently has a consensus price target of $32.20, suggesting a potential upside of 31.84%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Nurix Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 1 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.81 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend IMNM or AVTE?

Immunome presently has a consensus price target of $33.17, suggesting a potential upside of 37.71%. Given Immunome's stronger consensus rating and higher probable upside, analysts plainly believe Immunome is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.85 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is IMNM or AVTE more profitable?

Immunome's return on equity of -51.15% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -51.15% -47.32% Aerovate Therapeutics N/A -90.19% -77.47%

Do analysts rate KOD or AVTE?

Kodiak Sciences presently has a consensus target price of $42.14, indicating a potential upside of 11.03%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, KOD or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is KOD or AVTE more profitable?

Aerovate Therapeutics' return on equity of -90.19% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Aerovate Therapeutics N/A -90.19% -77.47%

Aerovate Therapeutics (AVTE) Competitors

$21.30 -0.21 (-0.98%)

As of 07/6/2026

Compare

AVTE vs. MBX, ABCL, NRIX, IMNM, and KOD

Should you buy Aerovate Therapeutics stock or one of its competitors? MarketBeat compares Aerovate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aerovate Therapeutics include MBX Biosciences (MBX), AbCellera Biologics (ABCL), Nurix Therapeutics (NRIX), Immunome (IMNM), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does Aerovate Therapeutics compare to MBX Biosciences?

Aerovate Therapeutics (NASDAQ:AVTE) and MBX Biosciences (NASDAQ:MBX) are both pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

MBX Biosciences has a consensus target price of $60.22, indicating a potential upside of 2.04%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

MBX Biosciences' return on equity of -24.52% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
MBX Biosciences	N/A	-24.52%	-23.59%

In the previous week, MBX Biosciences had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for MBX Biosciences and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 equaled MBX Biosciences'average media sentiment score.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
MBX Biosciences	Neutral

MBX Biosciences is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

Summary

MBX Biosciences beats Aerovate Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Aerovate Therapeutics compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

In the previous week, AbCellera Biologics had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 5 mentions for AbCellera Biologics and 0 mentions for Aerovate Therapeutics. AbCellera Biologics' average media sentiment score of 0.72 beat Aerovate Therapeutics' score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Overall Sentiment
AbCellera Biologics	Positive
Aerovate Therapeutics	Neutral

61.4% of AbCellera Biologics shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AbCellera Biologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

AbCellera Biologics presently has a consensus target price of $8.33, indicating a potential upside of 5.66%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe AbCellera Biologics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aerovate Therapeutics has lower revenue, but higher earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	32.06	-$146.41M	-$0.48	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Aerovate Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

AbCellera Biologics beats Aerovate Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Aerovate Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -411.37%. Nurix Therapeutics' return on equity of -64.21% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-411.37%	-64.21%	-48.44%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

In the previous week, Nurix Therapeutics had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 4 mentions for Nurix Therapeutics and 0 mentions for Aerovate Therapeutics. Nurix Therapeutics' average media sentiment score of 0.31 beat Aerovate Therapeutics' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nurix Therapeutics	Neutral
Aerovate Therapeutics	Neutral

Aerovate Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	30.07	-$264.46M	-$3.16	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Nurix Therapeutics presently has a consensus price target of $32.20, suggesting a potential upside of 31.84%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Nurix Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nurix Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Summary

Nurix Therapeutics beats Aerovate Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Immunome?

Immunome (NASDAQ:IMNM) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Immunome has a beta of 2.07, indicating that its stock price is 107% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Immunome presently has a consensus price target of $33.17, suggesting a potential upside of 37.71%. Given Immunome's stronger consensus rating and higher probable upside, analysts plainly believe Immunome is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

44.6% of Immunome shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aerovate Therapeutics has lower revenue, but higher earnings than Immunome. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	393.03	-$212.39M	-$2.38	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

In the previous week, Immunome had 6 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Immunome and 0 mentions for Aerovate Therapeutics. Immunome's average media sentiment score of 0.34 beat Aerovate Therapeutics' score of 0.00 indicating that Immunome is being referred to more favorably in the media.

Company	Overall Sentiment
Immunome	Neutral
Aerovate Therapeutics	Neutral

Immunome's return on equity of -51.15% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-51.15%	-47.32%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

Immunome beats Aerovate Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Kodiak Sciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

89.1% of Kodiak Sciences shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kodiak Sciences presently has a consensus target price of $42.14, indicating a potential upside of 11.03%. Given Kodiak Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Kodiak Sciences' average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Kodiak Sciences	Neutral
Aerovate Therapeutics	Neutral

Aerovate Therapeutics' return on equity of -90.19% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Summary

Kodiak Sciences beats Aerovate Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTE vs. The Competition

Export

Metric	Aerovate Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$617.38M	$955.37M	$7.00B	$12.42B
Dividend Yield	N/A	4.84%	2.67%	6.52%
P/E Ratio	-7.12	1.60	27.36	24.48
Price / Sales	N/A	114.19	536.36	94.85
Price / Cash	N/A	22.05	29.65	49.23
Price / Book	5.38	8.26	10.81	6.41
Net Income	-$75.52M	-$3.96M	$3.56B	$335.81M
7 Day Performance	-3.66%	-1.51%	2.19%	1.92%
1 Month Performance	25.74%	2.66%	7.15%	5.22%
1 Year Performance	91.20%	47.78%	35.43%	24.96%

Aerovate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTE Aerovate Therapeutics	N/A	$21.30 -1.0%	N/A	+93.1%	$617.38M	N/A	N/A	20	High Trading Volume
MBX MBX Biosciences	0.8902 of 5 stars	$55.20 +2.5%	$60.22 +9.1%	N/A	$2.56B	N/A	N/A	N/A
ABCL AbCellera Biologics	1.1709 of 5 stars	$7.84 -3.4%	$7.80 -0.5%	+106.8%	$2.48B	$75.13M	N/A	500	News Coverage Analyst Upgrade Gap Up
NRIX Nurix Therapeutics	3.1749 of 5 stars	$24.26 +1.7%	$32.20 +32.7%	+88.8%	$2.47B	$83.98M	N/A	300	Upcoming Earnings
IMNM Immunome	2.9724 of 5 stars	$21.19 +0.7%	$33.17 +56.5%	+174.4%	$2.38B	$6.94M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTE) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. MBX, ABCL, NRIX, IMNM, and KOD

How does Aerovate Therapeutics compare to MBX Biosciences?

Summary

How does Aerovate Therapeutics compare to AbCellera Biologics?

Summary

How does Aerovate Therapeutics compare to Nurix Therapeutics?

Summary

How does Aerovate Therapeutics compare to Immunome?

Summary

How does Aerovate Therapeutics compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. MBX, ABCL, NRIX, IMNM, and KOD

How does Aerovate Therapeutics compare to MBX Biosciences?

Do analysts rate AVTE or MBX?

Is AVTE or MBX more profitable?

Does the media refer more to AVTE or MBX?

Which has stronger earnings & valuation, AVTE or MBX?

Which has more volatility & risk, AVTE or MBX?

Summary

How does Aerovate Therapeutics compare to AbCellera Biologics?

Does the media prefer ABCL or AVTE?

Do institutionals & insiders believe in ABCL or AVTE?

Which has more volatility and risk, ABCL or AVTE?

Do analysts recommend ABCL or AVTE?

Which has better earnings and valuation, ABCL or AVTE?

Is ABCL or AVTE more profitable?

Summary

How does Aerovate Therapeutics compare to Nurix Therapeutics?

Is NRIX or AVTE more profitable?

Does the media favor NRIX or AVTE?

Which has better valuation and earnings, NRIX or AVTE?

Do analysts rate NRIX or AVTE?

Which has more risk and volatility, NRIX or AVTE?

Summary

How does Aerovate Therapeutics compare to Immunome?

Which has more volatility and risk, IMNM or AVTE?

Do analysts recommend IMNM or AVTE?

Do institutionals & insiders hold more shares of IMNM or AVTE?

Which has higher valuation and earnings, IMNM or AVTE?

Does the media prefer IMNM or AVTE?

Is IMNM or AVTE more profitable?

Summary

How does Aerovate Therapeutics compare to Kodiak Sciences?

Which has preferable earnings & valuation, KOD or AVTE?

Which has more volatility and risk, KOD or AVTE?

Do insiders and institutionals believe in KOD or AVTE?

Do analysts rate KOD or AVTE?

Does the media prefer KOD or AVTE?

Is KOD or AVTE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools